Anatara Lifesciences Limited announced the following Board changes. As of 7 December 2022, Sue MacLeman will retire as Non-Executive Director at Anatara as foreshadowed at the Company's AGM in November. Sue joined the Anatara Board as Non-Executive Chair in August 2018, providing valuable guidance throughout the Company's transition beyond animal health to the clinical validation of gastrointestinal health products for humans.

Sue has chaired the Audit and Risk Committee since stepping back from the Non-Executive Chair role in 2021. The Board sincerely thanks Sue for her commitment and guidance over the last four years. As of 7 December 2022, Nick Haslam has been appointed as Non-Executive Director at Anatara.

Nick is a chartered accountant with ten years of experience in professional services within M&A and restructuring at PwC. Nick is currently the Chief Executive Officer of Plasma Shield Limited, an Australian medical device company. Additionally, Nick held commercial leadership roles within professional sports, which included scaling up KangaTech, a medical device and injury prevention business, with customers spread across Australia, the US and Europe.